{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:03:29Z","timestamp":1792839809740,"version":"4.5.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,2,4]]},"abstract":"\n Importance<\/jats:title>\n Standard care for preventing mother-to-child transmission (MTCT) of hepatitis B virus (HBV) in highly viremic mothers consists of maternal antiviral prophylaxis beginning at gestational week 28 combined with an HBV vaccine series and HBV immune globulin (HBIG) at birth. However, HBIG is unavailable in some resource-limited areas.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether initiating tenofovir disoproxil fumarate (TDF) at gestational week 16 combined with HBV vaccinations for infants is noninferior to the standard care of TDF at gestational week 28 combined with HBV vaccinations and HBIG for infants in preventing MTCT in mothers with HBV and high levels of viremia.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n An unblinded, 2-group, randomized, noninferiority clinical trial was conducted in 7 tertiary care hospitals in China. A total of 280 pregnant individuals (who all identified as women) with HBV DNA levels greater than 200\u202f000 IU\/mL were enrolled between June 4, 2018, and February 8, 2021. The final follow-up occurred on March 1, 2022.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Pregnant individuals were randomly assigned to receive either TDF starting at gestational week 16 with HBV vaccinations for the infant or TDF starting at gestational week 28 with HBV vaccinations and HBIG administered to the infant.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the MTCT rate, defined as detectable HBV DNA greater than 20 IU\/mL or hepatitis B surface antigen positivity in infants at age 28 weeks. Noninferiority was established if the MTCT rate in the experimental group did not increase by more than an absolute difference of 3% compared with the standard care group, as measured by the upper limit of the 2-sided 90% CI.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 280 pregnant individuals who enrolled in the trial (mean age, 28 years; mean gestational age at enrollment, 16 weeks), 265 (95%) completed the study. Among all live-born infants, using the last observation carried forward, the MTCT rate was 0.76% (1\/131) in the experimental group and 0% (0\/142) in the standard care group. In the per-protocol analysis, the MTCT rate was 0% (0\/124) in the experimental group and 0% (0\/141) in the standard care group. The between-group difference was 0.76% (upper limit of the 2-sided 90% CI, 1.74%) in all live-born infants and 0% (upper limit of the 2-sided 90% CI, 1.43%) in the per-protocol analysis. Both comparisons met the criterion for noninferiority. Rates of congenital defects and malformations were 2.3% (3\/131) in the experimental group and 6.3% (9\/142) in the standard care group (difference, 4% [2-sided 95% CI, \u22128.8% to 0.7%]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Among pregnant women with HBV and high levels of viremia, TDF beginning at gestational week 16 combined with HBV vaccination for infants was noninferior to the standard care of TDF beginning at gestational week 28 combined with HBIG and HBV vaccination for infants. These results support beginning TDF at gestational week 16 combined with infant HBV vaccine to prevent MTCT of HBV in geographic areas where HBIG is not available.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03476083<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2024.22952","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T09:30:39Z","timestamp":1731576639000},"page":"390","source":"Crossref","is-referenced-by-count":29,"title":["Tenofovir and Hepatitis B Virus Transmission During Pregnancy"],"prefix":"10.1001","volume":"333","author":[{"given":"Calvin Q.","family":"Pan","sequence":"first","affiliation":[{"name":"Guangzhou Medical Research Institute of Infectious Diseases, Center for Liver Diseases, Guangzhou Eighth People\u2019s Hospital, Guangzhou Medical University, Guangzhou, China"},{"name":"Division of Gastroenterology, Department of Medicine, NYU Langone Medical Center, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhei","family":"Dai","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongfu","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shijiazhuang Maternity and Child Healthcare Hospital, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Beijing Youan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Q.","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University, Guangzhou, China"},{"name":"Department of Obstetrics and Gynecology, University of Arizona College of Medicine, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Wang","sequence":"additional","affiliation":[{"name":"Southwest University Public Health Hospital, Chongqing, China"},{"name":"Department of Infectious Diseases, Southwest Hospital, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department for Infectious Diseases, Shenzhen Third People\u2019s Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuili","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shijiazhuang Maternity and Child Healthcare Hospital, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Chen","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaibin","family":"Zou","sequence":"additional","affiliation":[{"name":"The Fourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"joi240130r1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.","volume":"8","author":"Polaris Observatory Collaborators","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"joi240130r2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.7150\/ijms.2.36","article-title":"Natural history and clinical consequences of hepatitis B virus infection.","volume":"2","author":"Pan","year":"2005","journal-title":"Int J Med Sci"},{"issue":"2","key":"joi240130r3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cld.2015.01.001","article-title":"Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.","volume":"19","author":"McGlynn","year":"2015","journal-title":"Clin Liver Dis"},{"issue":"5","key":"joi240130r5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.cgh.2011.10.041","article-title":"An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus.","volume":"10","author":"Pan","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"joi240130r6","doi-asserted-by":"publisher","DOI":"10.1177\/13596535221076640","article-title":"The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B.","volume":"27","author":"Pan","year":"2022","journal-title":"Antivir Ther"},{"issue":"8","key":"joi240130r7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.15585\/mmwr.mm6808a2","article-title":"Progress toward hepatitis B control and elimination of mother-to-child transmission of hepatitis B virus\u2014Western Pacific Region, 2005-2017.","volume":"68","author":"Woodring","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"joi240130r8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.","volume":"3","author":"Polaris Observatory Collaborators","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"joi240130r9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.11604\/pamj.supp.2017.27.3.11981","article-title":"The status of hepatitis B control in the African region.","volume":"27","author":"Breakwell","year":"2017","journal-title":"Pan Afr Med J"},{"key":"joi240130r10","doi-asserted-by":"publisher","DOI":"10.26633\/RPSP.2017.159","article-title":"Progress towards a comprehensive approach to maternal and neonatal immunization in the Americas.","volume":"41","author":"Ropero Alvarez","year":"2017","journal-title":"Rev Panam Salud Publica"},{"issue":"8","key":"joi240130r11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1473-3099(22)00206-7","article-title":"Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial.","volume":"22","author":"Segeral","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"joi240130r12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/jmv.10071","article-title":"Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants.","volume":"67","author":"Milne","year":"2002","journal-title":"J Med Virol"},{"issue":"4","key":"joi240130r13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/infdis\/152.4.817","article-title":"Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers.","volume":"152","author":"Lo","year":"1985","journal-title":"J Infect Dis"},{"issue":"10","key":"joi240130r14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.11622\/smedj.2015194","article-title":"Limited benefit of hepatitis B immunoglobulin prophylaxis in children of hepatitis B e antigen-negative mothers.","volume":"57","author":"Lee","year":"2016","journal-title":"Singapore Med J"},{"issue":"2","key":"joi240130r15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/jac\/dku404","article-title":"Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+\/HBeAg- mothers: a systematic review and meta-analysis.","volume":"70","author":"Machaira","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"joi240130r16","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1111\/j.1365-2893.2011.01492.x","article-title":"Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers.","volume":"19","author":"Zou","year":"2012","journal-title":"J Viral Hepat"},{"issue":"24","key":"joi240130r17","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load.","volume":"374","author":"Pan","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"joi240130r20","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u00df-Lactam monotherapy vs \u00df-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"16","key":"joi240130r21","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1056\/NEJMoa061752","article-title":"Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis.","volume":"355","author":"Mas","year":"2006","journal-title":"N Engl J Med"},{"issue":"10079","key":"joi240130r22","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"joi240130r23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/hep.27034","article-title":"Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice.","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"issue":"12","key":"joi240130r24","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/apt.14068","article-title":"Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus.","volume":"45","author":"Hyun","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"joi240130r25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1365-2893.2008.01056.x","article-title":"Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study.","volume":"16","author":"Xu","year":"2009","journal-title":"J Viral Hepat"},{"issue":"9324","key":"joi240130r26","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"issue":"9606","key":"joi240130r27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0140-6736(08)60074-4","article-title":"Epidemiology and causes of preterm birth.","volume":"371","author":"Goldenberg","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"joi240130r28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ijgo.13195","article-title":"Global burden of preterm birth.","volume":"150","author":"Walani","year":"2020","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"joi240130r29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251552","article-title":"Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.","volume":"16","author":"Pan","year":"2021","journal-title":"PLoS One"},{"key":"joi240130r30","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1186\/1471-2334-13-524","article-title":"Dynamic changes of HBV markers and HBV DNA load in infants born to HBsAg(+) mothers: can positivity of HBsAg or HBV DNA at birth be an indicator for HBV infection of infants?","volume":"13","author":"Chen","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"4","key":"joi240130r32","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/cid\/ciae288","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for preventing vertical transmission in chronic hepatitis b mothers: a systematic review and meta-analysis.","volume":"79","author":"Pan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"joi240130r4","unstructured":"WHO. Prevention of mother-to-child transmission of hepatitis B virus: WHO guidelines on antiviral prophylaxis in pregnancy. July 27, 2020. Accessed May 8, 2024. https:\/\/www.who.int\/publications\/i\/item\/978-92-4-000270-8"},{"key":"joi240130r18","unstructured":"WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 1, 2015. Accessed May 8, 2024. https:\/\/www.who.int\/publications\/i\/item\/9789241509565"},{"key":"joi240130r19","unstructured":"FDA. Non-inferiority clinical trials to establish effectiveness\u2014FDA guidance for industry. November 2016. Accessed January 10, 2024. https:\/\/www.fda.gov\/media\/78504\/download"},{"key":"joi240130r31","unstructured":"The Antiviral Pregnancy Registry. Antiviral Pregnancy Registry interim report\u20141 January 1989 through 31 July 2023. December 2023. Accessed May 8, 2024. http:\/\/www.apregistry.com"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2826316\/jama_pan_2024_oi_240130_1737659635.44214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T11:11:08Z","timestamp":1738667468000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2826316"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,2,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.22952","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,4]]}}}